NWBO

Northwest Biotherapeutics, Inc. [NWBO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NWBO Stock Summary

Top 10 Correlated ETFs

NWBO

Top 10 Correlated Stocks

NWBO

In the News

NWBO Financial details

Company Rating
-
Market Cap
618.78M
Income
-62.23M
Revenue
1.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-9.15
Forward P/E
-
PEG
1.59
P/S
359.78
P/B
-11.32
P/C
-
P/FCF
-14.79
Quick Ratio
0.14
Current Ratio
0.17
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.99%
Revenue last 5Y
-4.33%
Revenue Q/Q
9.61%
EPS Q/Q
-2.38%
-
-
-
-
SMA20
20.83%
SMA50
20.83%
SMA100
11.54%
Inst Own
-
Inst Trans
-
ROA
-256%
ROE
104%
ROC
3.3%
Gross Margin
100%
Oper. Margin
-2809%
Profit Margin
-3865%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-1.09
52W High
-
52W Low
-
RSI
57.15
Rel Volume
0.43
Avg Volume
1.79M
Volume
761.85K
Perf Week
-3.32%
Perf Month
22.88%
Perf Quarter
16.51%
Perf Half Y
15.25%
-
-
-
-
Beta
-0.698
-
-
Volatility
0%, 0.02%
Prev Close
0.25%
Price
0.29
Change
-1.49%

Something similar

Top by Market Cap
MIX.JO
BRYN.DE
BRK-B
V
LLY.DE
Top Correlated ETFs
BLOK
NLR
BKCH
STCE
WESE.PA
Top Correlated Stocks
0960.HK
STEM
0817.HK
FLR
CHSCN
Similar Market Cap
VLE.TO
2136.HK
HABA.HM
DRD
0LEC.L

Company Profile

Healthcare Biotechnology
  • Volume Average 1.79M
  • Market Capitalization 618.78M
  • Employee 25
  • CEO Ms. Linda F. Powers J.D.
  • Headquarters Bethesda,MD,US
  • IPO Date 2001-12-14
  • Website https://www.nwbio.com

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.